&nbsp;

Sep 2024

Drug

riTUXimab

Other Name(s): Rituxan® , Truxima™ , Riximyo™ , Ruxience™ , Riabni™

Quick Link(s):

Oct 2023

Drug

regorafenib

Other Name(s): Stivarga®

Quick Link(s):

Nov 2023

Drug

romidepsin

Other Name(s): Istodax®

Quick Link(s):

Mar 2023

Drug

ramucirumab

Other Name(s): Cyramza®

Quick Link(s):

Mar 2023

Regimen

RITU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) - Single Agent - Indolent Lymphoma

Drugs Used:

riTUXimab

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

RITU(MNT)

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma

Drugs Used:

riTUXimab

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

REGO

Cancer Type:

Gastrointestinal,

Colorectal

Intent: Palliative

Drugs Used:

regorafenib (Unfunded)

Quick Link(s):

Regimen Monograph

Aug 2023

Regimen

REGO

Cancer Type:

Gastrointestinal,

Gastrointestinal Stromal Tumours,

Sarcoma,

GIST

Intent: Palliative

Funding:

Exceptional Access Program

Drugs Used:

regorafenib

Quick Link(s):

Regimen Monograph

Aug 2023

Regimen

RAMU

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Drugs Used:

ramucirumab (Unfunded)

Quick Link(s):

Regimen Monograph

Mar 2023

Regimen

RALT

Cancer Type:

Gastrointestinal,

Colorectal,

Esophagus,

Gastric / Stomach,

Small bowel and appendix

Intent: Adjuvant, Palliative

Funding:

New Drug Funding Program

Raltitrexed - Metastatic Colorectal Small Bowel or Appendiceal Cancer

New Drug Funding Program

Raltitrexed - Metastatic Esophageal, Gastroesophageal Junction, or Gastric Cancer

New Drug Funding Program

Raltitrexed - Adjuvant Colorectal, Small Bowel, or Appendiceal Cancer

New Drug Funding Program

Raltitrexed - Adjuvant Esophageal, Gastroesophageal Junction, or Gastric Cancer

Drugs Used:

raltitrexed

Quick Link(s):

Regimen Monograph

Jun 2024

Regimen

REGO

Cancer Type:

Gastrointestinal,

Hepatobiliary / Liver / Bile Duct

Intent: Palliative

Funding:

Exceptional Access Program

regorafenib - For the treatment of unresectable, advanced hepatocellular carcinoma (HCC) according to clinical criteria

Drugs Used:

regorafenib